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Genome-wide association study of behavioural and psychiatric
features in human prion disease
AGB Thompson
1,2, J Uphill
1, J Lowe
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1,2, A Lukic
1,2, C Carswell
1,2, P Rudge
1,2, A MacKay
3, J Collinge
1,2 and S Mead
1,2
Prion diseases are rare neurodegenerative conditions causing highly variable clinical syndromes, which often include prominent
neuropsychiatric symptoms. We have recently carried out a clinical study of behavioural and psychiatric symptoms in a large
prospective cohort of patients with prion disease in the United Kingdom, allowing us to operationalise speciﬁc behavioural/
psychiatric phenotypes as traits in human prion disease. Here, we report exploratory genome-wide association analysis on 170 of
these patients and 5200 UK controls, looking for single-nucleotide polymorphisms (SNPs) associated with three behavioural/
psychiatric phenotypes in the context of prion disease. We also speciﬁcally examined a selection of candidate SNPs that have
shown genome-wide association with psychiatric conditions in previously published studies, and the codon 129 polymorphism of
the prion protein gene, which is known to modify various aspects of the phenotype of prion disease. No SNPs reached genome-
wide signiﬁcance, and there was no evidence of altered burden of known psychiatric risk alleles in relevant prion cases. SNPs
showing suggestive evidence of association (Po10
−5) included several lying near genes previously implicated in association
studies of other psychiatric and neurodegenerative diseases. These include ANK3, SORL1 and a region of chromosome 6p
containing several genes implicated in schizophrenia and bipolar disorder. We would encourage others to acquire phenotype data
in independent cohorts of patients with prion disease as well as other neurodegenerative and neuropsychiatric conditions, to allow
meta-analysis that may shed clearer light on the biological basis of these complex disease manifestations, and the diseases
themselves.
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INTRODUCTION
The human prion diseases are a group of rare neurodegenerative
conditions that occur in sporadic, inherited and acquired forms.
1
Their clinical manifestations are highly variable both within and
between these different aetiological types, and often include
prominent neuropsychiatric symptomatology.
2,3 The causes of this
clinical heterogeneity are incompletely understood. Some modi-
ﬁers of the clinical phenotype are well established, such as the
polymorphic genotype at codon 129 of the prion protein gene
(PRNP), but known factors only account for a small minority of the
total variability seen.
4–6
Clinical study of these diseases is challenging because of their
rarity and their typically rapid progression, which makes detailed
prospective follow-up difﬁcult to achieve. Psychiatric symptoms
are particularly difﬁcult to study as patients often have substantial
cognitive impairment with limited expressive language function
by the time the diagnosis is made, so they are unable to describe
their internal experiences to allow their symptoms to be
characterized. Further, psychiatric manifestations are often intense
but transient.
7
We recently undertook a large clinical study of behavioural
disturbance and psychiatric symptoms (BPS) in human prion
disease in the context of the National Prion Monitoring Cohort
(‘the Cohort’), an ongoing prospective natural history study that
has aimed to recruit all patients with all types of prion disease in
the United Kingdom since October 2008. This used clinical data
from more than 300 patients enrolled in the Cohort and/or the
preceding PRION-1 clinical trial to characterize in as much detail as
possible the range of BPS seen in prion disease, as well as their
prevalence, natural history and observed response to sympto-
matic treatments. The clinical aspects of this work have now been
published.
7 Full methodological details of the PRION-1 trial and
the Cohort study have been published previously.
8,9
A large number of patients included in these clinical studies
were included in a genome-wide association study (GWAS) of
susceptibility to prion disease,
10 and therefore have single-
nucleotide polymorphism (SNP) genotype data publicly available.
This GWAS found that several SNPs at the PRNP locus itself were
very strongly associated with all types of prion disease, with this
association being driven by linkage disequilibrium with the
polymorphism at codon 129 (which was itself one of the
genotyped SNPs). No other SNPs reached genome-wide signiﬁ-
cance, and no SNPs that had previously been found to show
genome-wide association with other neurodegenerative diseases
showed any association with prion disease.
The detailed clinical data regarding the presence or absence of
BPS established for our recent clinical study allows us to
operationalise speciﬁc behavioural/psychiatric phenotypes as
traits in human prion disease, and thereby presents the
opportunity to carry out a GWAS looking for genetic modiﬁers
of these traits. A similar approach has previously been taken in
other neurodegenerative diseases that may cause psychiatric
symptoms, such as Alzheimer’s disease,
11 and this approach has
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that may underlie these complex disease manifestations.
MATERIALS AND METHODS
All patients were referred to the NHS National Prion Clinic, and were
enrolled in the PRION-1 trial and/or the National Prion Monitoring Cohort.
Uptake of enrolment in these clinical research studies is extremely high
(495% in the Cohort), so they provide a highly representative sample of
patients seen in this clinical setting. Patients were diagnosed with probable
sporadic Creutzfeldt-Jakob disease (CJD) according to World Health
Organisation criteria with the addition of brain MRI as a supportive
investigation as recommended by the MRI-CJD consortium.
12 Variant CJD
was diagnosed using established criteria.
13 Patients were diagnosed with
inherited prion disease if PRNP genotyping showed the presence of a
pathogenic mutation in the presence of a consistent clinical syndrome. All
patients included in this study underwent diagnostic genotyping to
conﬁrm or rule out the presence of a pathogenic PRNP mutation. Patients
were diagnosed with iatrogenic CJD using sporadic CJD criteria in the
presence of a history of relevant exposure (for example, to implicated
cadaveric human growth hormone). Approximately 2/3 of patients had
neuropathological examination of brain tissue (post mortem or from
biopsy), or tonsil biopsy (for variant CJD), which was used to conﬁrm the
diagnosis.
Clinical data from PRION-1 and the Cohort
PRION-1 was an open-label, patient preference trial of quinacrine for all
types of human prion disease, which recruited patients from 2001 to 2008.
The trial showed no effect of quinacrine on survival or any of the rating
scales used as secondary outcome measures.
8,14 The National Prion
Monitoring Cohort is an ongoing natural history study of all types of prion
disease, which has been enrolling patients since October 2008.
9
In both studies, patients were enrolled and followed up throughout their
disease course whenever possible, with clinical data recorded by a
neurologist at each assessment. For the analysis below, three particular
sets of data were used to identify patients with BPS:
First symptoms: at enrolment, all patients and/or carers were
asked to recall the ﬁrst symptom that had been noticed or
reported when the illness began. If more than one symptom was
felt to have appeared together these were all included. It was
speciﬁcally recorded whether behavioural and psychiatric symp-
toms were among these ﬁrst symptoms for all patients.
Symptoms at time of assessment: the presence and severity/
frequency of a range of speciﬁc symptoms were recorded at each
assessment. These included ‘hallucinations’ and ‘depressive
symptoms’.
Indications for drug prescription: details of all drugs prescribed
during the period of study were recorded, including indication for
treatment.
The clinical case notes of selected patients identiﬁed from the research
data, including all of those prescribed medication for BPS, were reviewed
in detail by one of the authors (AGBT) to conﬁrm the presence and nature
of the clinical features.
These sources of clinical information were combined to classify each
patient on the basis of three speciﬁc behavioural/psychiatric phenotypes:
￿ Presence of any behavioural disturbance or psychiatric symp-
toms at the onset of the illness (that is, among the ﬁrst
symptoms).
￿ Presence of psychotic features (hallucinations and delusions) at
any stage of the illness.
￿ Presence of mood disorder (including low mood, emotional
lability, apathy and withdrawal) at any stage of the illness.
Genome-wide association analysis was performed on 170 cases (114
sporadic CJD, 33 inherited prion disease, 22 variant CJD and 1 iatrogenic
CJD) and 5200 UK controls provided by the Wellcome Trust Case Control
Consortium. Controls were genotyped on the Illumina 1.2M Custom Duo
array; cases on the Illumina 660K array (Illumina, San Diego, CA, USA).
Analyses were carried out comparing (1) cases with each phenotype (prion
+) with cases without the phenotype (prion–), and (2) prion+ cases with
controls (that is, total of six analyses).
All of these individuals had been genotyped previously for inclusion in a
GWAS of susceptibility to prion disease,
10 and full details of patient and
control samples, genotyping and quality control are included in that paper.
In the current study, Fisher’s exact test was used for the association
analyses because of the relatively small number of patients. 518938 SNPs
were included in the analysis after quality control. Ethnic outliers detected
using a multidimensional scaling plot were excluded. Data manipulation
and statistical analysis were carried out using PLINK (http://pngu.mgh.
harvard.edu/purcell/plink/).
The rationale for including a comparison of prion+ cases with controls
was that if a hypothetical risk allele existed for a psychiatric phenotype in
the context of prion disease, then it would be expected to be most
common in prion+ cases, followed by controls (who may include
individuals that would be at risk if they were to develop prion disease),
followed by prion− cases (who have not developed the phenotype
despite having prion disease). The comparison with controls would
therefore produce an odds ratio (OR) closer to 1, but nevertheless might be
more likely to show a high level of statistical signiﬁcance because of the
much larger numbers of individuals included, whereas the comparison
with prion− cases would be expected to produce a larger OR but might
fail to reach such high levels of statistical signiﬁcance. As all of these
individuals were previously included in the GWAS of susceptibility to prion
disease,
10 which showed no strong associations apart from SNPs at the
PRNP locus itself, it would not be expected that association with prion
disease itself would lead to spurious strong associations in the prion+ vs
controls analysis, and if this was the case then the same SNP would not be
expected to show any association in the prion+ vs prion− analysis.
We also planned to speciﬁcally examine a small selection of candidate
SNPs in a hypothesis-driven manner, in light of the limited statistical power
that could be achieved in the genome-wide analysis, given the relatively
small number of cases. We reviewed previously published GWASs in
psychiatric conditions characterised by psychosis and/or mood disorder
(schizophrenia,
15 bipolar affective disorder
16–18 and major depressive
disorder
19 to identify a list of candidate SNPs that have shown association
with these conditions at genome-level signiﬁcance, on the basis that these
might also show association with the behavioural/psychiatric phenotypes
in prion disease. These SNPs are listed in Table 1. We also included the
codon 129 polymorphism of PRNP (SNP rs1799990), as this is known to
modify other aspects of the phenotype of prion disease (for example, rate
of disease progression, and incubation time in acquired prion disease) and
also to confer susceptibility to prion disease (as shown in the GWAS for
prion disease mentioned above
10). There was no evidence of population
structure in the United Kingdom and no corrections were made.
RESULTS
Table 2 shows details of the SNPs with the most signiﬁcant
associations in each analysis. No SNPs reached the standard
threshold for GWASs (Po5×10
−8). All data are publicly available.
The single most signiﬁcant association was in the prion+ vs
controls analysis for psychiatric symptoms at onset, for a SNP
(rs10509125) lying within the Ankyrin 3 (ANK3) gene
(P=1.43×10
−6, OR=2.09) (see Table 2). In the prion+ vs
prion− analysis, association for this SNP was less signiﬁcant but
effect size was greater (P=3.5×10
−5, OR=2.52).
A cluster of three SNPs on chromosome 6p were most strongly
associated with the presence of psychotic features in the prion+ vs
controls analysis (rs1055569; P=2.66×10
−6, OR=2.36), and also
showed association in the prion+ vs prion– analysis
(P=1.08×10
−4, OR=2.49). These SNPs span the 5′ end of the
non-protein-coding human leukocyte antigen complex group 26
(HCG26) gene.
The most signiﬁcant association in the mood disorder analyses
was in the prion+ vs controls analysis for a SNP lying within the
acylglycerol kinase (AGK) gene (rs7789850; P=2.16×10
−6,O R =
4.6). AGK encodes a mitochondrial membrane protein involved in
lipid and glycerolipid metabolism.
Closely associated SNPs rs1219407 and rs478903, which showed
the strongest association with mood disorder in the prion+ vs
GWAS of behavioural and psychiatric features in prion disease
AGB Thompson et al
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Translational Psychiatry (2015), 1–6prion− analysis, lie about 200kb from the SORL1 gene. rs6867820,
another SNP that showed association with mood disorder in our
analyses, lies 55 kb from the SNCAIP gene, which encodes
Synphilin-1.
Table 1 summarises the association results for the candidate
SNPs identiﬁed from previously published GWAS in psychiatric
conditions (schizophrenia,
15 bipolar affective disorder
16–18 and
major depressive disorder
19 and in prion disease).
10 The SNP
implicated by the prion disease GWAS is PRNP codon 129. As this
SNP is known to be strongly associated with prion disease, it is not
meaningful to include results for the prion+ vs controls analysis
(as expected these showed strong association). None of the
candidate SNPs identiﬁed from GWAS in psychiatric conditions
showed evidence of association with the behavioural/psychiatric
phenotypes in prion disease in our analysis, in light of the number
of tests being performed. In addition, we performed an analysis of
the burden of risk alleles for psychiatric conditions (9 GWA loci
shown in Table 1 Po5x10
−8) by the score method using PLINK.
We weighted allele contributions based on the logarithm of OR in
the discovery study. There were no statistically signiﬁcant
differences between mean scores for prion+ vs prion− or prion
+ vs controls (six tests, all P40.1).
DISCUSSION
We have performed exploratory candidate SNP, risk allele burden
and genome-wide association studies to look for evidence of
genetic loci associated with three behavioural/psychiatric pheno-
types in the context of prion disease. As the number of patients
included is small, these studies are only powered to detect very
strongly associated SNPs, and the lack of any reaching genome-
wide signiﬁcance certainly does not rule out the possibility of
major genetic modiﬁers of these phenotypes. Patients with all
prion disease types were considered together in this analysis, so it
is possible that aetiology-speciﬁc associations may have been
missed or underestimated. The main aims of the study were to
establish feasibility of this approach and to test for a broad role of
a limited number of deﬁnite genetic risk factors discovered in
primary psychiatric disease.
Hypotheses are proposed here for follow-up in other cohorts of
prion disease or related neurodegenerative diseases.
11 Reviewing
the most strongly associated SNPs from our study we identiﬁed
several loci that may be of interest, as they have previously been
implicated in genetic studies of psychiatric or other neurodegen-
erative disorders.
The strongest evidence of association was for a SNP lying within
the ANK3 gene, in the analysis of psychiatric features at onset.
There is strong evidence for association of other SNPs within ANK3
with bipolar disorder from a large collaborative GWAS,
16 although
the genotyped SNPs reported in that study showed no evidence
of association in our analysis (see Table 1). Ankyrin 3 is thought to
participate in the maintenance/targeting of ion channels and cell
adhesion molecules at the nodes of Ranvier and initial axon
segments.
20
The SNPs on chromosome 6 that we found to be trending
towards association with psychotic features in prion disease lie
within a chromosomal region (6p21.3–22.1) that has been
implicated in genetic studies of susceptibility to both schizo-
phrenia and bipolar disorder, without a single locus emerging as
the dominant source of association.
15,21 It is possible that this
apparent inconsistency is related to the unusual patterns of
recombination around the major histocompatibility complex,
which also lies in this region.
22 Four of the top ﬁve candidate
genes for schizophrenia risk listed on SzGene.org lie within this
region (www.szgene.org). Although we must be conservative in
our conclusions because of the small patient numbers and the
failure of any SNPs to reach genome-wide signiﬁcance, this
suggestion of an overlap with the genetics of ‘primary’ psychiatric
disorders is intriguing.
Large GWASs using both SNPs and copy number variants have
previously identiﬁed genetic loci with an effect across multiple
psychiatric and neurodevelopmental conditions, with the overlap
between risk loci for schizophrenia and bipolar disorder being
particularly well established.
23–27 This has been interpreted as
evidence that there are genetic risk factors for psychosis that are
not disease speciﬁc.
25 It is conceivable that a genetic factor
conferring susceptibility to schizophrenia or bipolar disorder
might also increase the likelihood of an individual developing
psychotic features in the context of neurodegenerative disease.
Our results although negative, provide an intriguing hint that this
may be the case in prion disease, and we wish to encourage
further investigation of this hypothesis.
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